UQ1 Stock Chart & Stats
€34.25
-€0.80(-2.28%)
At close: 4:00 PM EDT
€34.25
-€0.80(-2.28%)
Day’s Range― - ―
52-Week Range€7.26 - €60.50
Previous CloseN/A
Volume0.00
Average Volume (3M)302.00
Market Cap
€2.62B
Enterprise Value€2.79K
Total Cash (Recent Filing)€810.34M
Total Debt (Recent Filing)€62.83M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 10, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.04
Shares Outstanding69,366,410
10 Day Avg. Volume21
30 Day Avg. Volume302
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.92
Price to Sales (P/S)85.48
P/FCF Ratio-7.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€56.92Price Target Upside66.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.39
Revenue Forecast (FY)€19.06M
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment — AMT-130Clear FDA agreement that 3-year AMT-130 data can serve as the primary basis for an accelerated BLA materially reduces regulatory uncertainty. This durable regulatory clarity shortens potential time to market under accelerated approval and supports planning for commercialization and confirmatory study alignment.
Strong Cash Runway & Recent Capital RaiseA cash balance of ~$810M and stated runway into 2030 materially reduces near-term financing risk, enabling funding of confirmatory trials, higher-dose cohorts, and commercialization build-out. This durable liquidity position supports execution of multi-year development programs without immediate dilution pressure.
Platform & Diversified Late‑stage PipelineuniQure's AAV platform and multiple programs in neurology and rare disease provide long-term optionality: early positive signals in AMT‑260 and biological activity in AMT‑191 increase the chance of at least one commercial success, and the licensing/collaboration model offers recurring partner revenue opportunities.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow near -$160M TTM indicates heavy ongoing investment and structural cash burn. Even with a strong current cash balance, prolonged negative cash flow requires disciplined spending or future financing, which can dilute equity or constrain strategic options long term.
Very Small Revenue Base Vs Large LossesRevenue remains minimal relative to operating scale, leaving the company reliant on milestone, collaboration, and financing events. Large negative margins demonstrate limited internal capacity to absorb R&D and commercialization costs, making sustainable profitability dependent on successful late‑stage outcomes or partner deals.
Clinical & Execution Risk (AMT‑191 Pause And Confirmatory Demands)A dosing pause for AMT‑191 and the FDA mandate that a confirmatory randomized trial be well underway by approval raise durable execution and safety risks. These constraints increase operational complexity, trial cost and timing, and could delay or condition approvals, affecting long‑term commercial prospects.
uniQure News
UQ1 FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was €7.26 and its highest was €60.50 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is €2.62B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Nov 10, 2026 which is in 96 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Jul 29, 2026. The company reported -€1.056 earnings per share for the quarter, missing the consensus estimate of -€0.711 by -€0.344.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.79.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 69,366,410 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -€1.056 in its last earnings report, missing expectations of -€0.711. Following the earnings report the stock price went up 7.623%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in DE:UQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€56.92 (66.19% Upside)
€56.92 (66.19% Upside)
Blogger Sentiment
Bullish
DE:UQ1 Sentiment 73%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €840.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
156.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
68.43%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
UQ1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed strong positive momentum: regulatory progress (FDA alignment on using 3-year data as the basis for an accelerated BLA), an on-track BLA/MAA submission timeline, upcoming 4-year AMT-130 data, encouraging early efficacy and biological signals in AMT-260 and AMT-191, and a materially strengthened balance sheet with ~$810M cash supporting operations into 2030. Notable challenges include a pause in higher-dose AMT-191 dosing after Grade 3 LFTs (dose-limiting toxicity), mixed early efficacy in the AMT-260 low-dose cohort, increased SG&A to fund commercialization (near-term burn), and the operational/regulatory requirement to have the confirmatory trial well underway at the time of any accelerated approval. Taken together, the positives (regulatory clarity, data momentum, cash runway, early signals) outweigh the manageable clinical and execution risks identified.View all DE:UQ1 earnings summariesUQ1 Stock 12 Month Forecast
Average Price Target
€56.92
▲(66.19% Upside)